STOCK TITAN

Edgewise Therapeutics, Inc. - EWTX STOCK NEWS

Welcome to our dedicated page for Edgewise Therapeutics news (Ticker: EWTX), a resource for investors and traders seeking the latest updates and insights on Edgewise Therapeutics stock.

Edgewise Therapeutics, Inc. (NASDAQ: EWTX) is a biotechnology company dedicated to the development of novel therapies for severe, rare muscle disorders. Headquartered in Boulder, Colorado, the company is renowned for its innovative approach to treating diseases involving skeletal muscle. Founded with Series A financing from OrbiMed, Edgewise Therapeutics is focused on the discovery, development, and commercialization of orally bioavailable, small molecule therapies designed to address musculoskeletal diseases.

The core mission of Edgewise Therapeutics is to transform the lives of patients suffering from debilitating muscle conditions. The company’s clinical-stage biopharmaceutical expertise is reflected in its robust pipeline of potential treatments, which aim to offer improved patient outcomes and enhanced quality of life.

Among its current projects, Edgewise Therapeutics is working on several promising candidates that target specific muscle-related conditions. By leveraging advanced research methodologies and cutting-edge technology, the company is able to create therapies that are not only effective but also accessible to a broader patient population.

Financially, Edgewise Therapeutics is well-positioned with strong backing from investors and strategic partners. The company continues to achieve significant milestones in its development programs, further solidifying its reputation as a leader in the biopharmaceutical landscape.

In recent news, Edgewise Therapeutics has made noteworthy progress with its clinical trials and has expanded its research partnerships to expedite the development of its drug candidates. The latest developments underline the company's commitment to innovation and excellence in the field of muscle disease therapeutics.

  • Location: Boulder, Colorado
  • Core Focus: Novel therapies for rare muscle disorders
  • Key Projects: Orally bioavailable small molecule therapies
  • Partnerships: Supported by OrbiMed and other strategic investors
Rhea-AI Summary

Edgewise Therapeutics (Nasdaq: EWTX) announced its participation at the 29th International Annual Congress of the World Muscle Society in Prague, October 8-12, 2024. The company will present an industry-sponsored symposium and seven scientific posters highlighting the effects of sevasemten in individuals with Becker muscular dystrophy.

The symposium, titled 'Understanding disease progression and a potential novel agent to protect muscle,' will feature key opinion leaders and discuss positive two-year topline results from the ARCH trial. The scientific posters will cover topics such as reduced muscle damage biomarkers, functional stabilization, and proteomic responses to sevasemten in Becker muscular dystrophy patients.

Sevasemten is an orally administered small molecule designed to prevent contraction-induced muscle damage in muscular dystrophies. The presentations will provide insights into biomarker and functional endpoints being studied in the CANYON Phase 2 trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.32%
Tags
conferences
-
Rhea-AI Summary

Edgewise Therapeutics (Nasdaq: EWTX) announced positive top-line data for EDG-7500, a novel oral cardiac sarcomere modulator, from its Phase 1 trial in healthy subjects and Phase 2 CIRRUS-HCM trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Key findings include:

1. Phase 1: EDG-7500 was well-tolerated without meaningful changes in left ventricle ejection fraction (LVEF).
2. CIRRUS-HCM: Single-dose trial demonstrated robust left ventricular outflow tract (LVOT) gradient reductions without significant LVEF changes.
3. 67% mean reduction in resting LVOT pressure gradient and 55% mean reduction in provokable LVOT gradient observed at 100 and 200 mg doses.
4. 64% mean reduction in NT-proBNP, a key heart failure biomarker, in the 200 mg cohort.

The company has initiated the 28-day part of CIRRUS-HCM in patients with obstructive and non-obstructive HCM, with initial data expected in Q1 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
54.69%
Tags
-
Rhea-AI Summary

Edgewise Therapeutics (Nasdaq: EWTX) has announced a live webcast scheduled for September 19, 2024, at 8:30 am ET to discuss top-line data of their drug EDG-7500. The presentation will cover results from two trials:

1. The Phase 1 trial in healthy subjects
2. The single-dose arm of the Phase 2 CIRRUS-HCM trial in patients with obstructive Hypertrophic Cardiomyopathy (HCM)

Dr. Anjali T. Owens, Medical Director at the Center for Inherited Cardiac Disease and Associate Professor of Medicine at the University of Pennsylvania, will join the management team to share her perspective on EDG-7500 and HCM. Interested parties can register for the webcast and access the accompanying slide presentation through the Edgewise events page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.5%
Tags
conferences clinical trial
Rhea-AI Summary

Edgewise Therapeutics (Nasdaq: EWTX) reported Q2 2024 financial results and business highlights. Key developments include:

1. Completed Phase 1 SAD and MAD trial of EDG-7500 in healthy volunteers

2. Dosing patients in Phase 2 CIRRUS-HCM trial of EDG-7500 for obstructive HCM

3. Advancing GRAND CANYON global pivotal cohort of sevasemten in adults with Becker muscular dystrophy

4. Progressing Phase 2 LYNX and FOX trials of sevasemten in children with Duchenne muscular dystrophy

5. Q2 2024 financial results: $511.8M cash and equivalents, R&D expenses $30.7M, G&A expenses $7.4M, net loss $31.5M ($0.34 per share)

The company expects to present topline data for EDG-7500 from Phase 1 and CIRRUS-HCM Part A in September 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.95%
Tags
-
Rhea-AI Summary

Edgewise Therapeutics, Inc. (Nasdaq: EWTX) will present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024, at 3:35 pm ET. The presentation will be webcast live and a replay will be available. Users should connect early for a timely connection.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.35%
Tags
conferences
-
Rhea-AI Summary

Edgewise Therapeutics, Inc. (Nasdaq: EWTX) reported financial results for Q1 2024, highlighting progress in their skeletal and cardiac muscle programs. Positive two-year results for sevasemten in Becker, advancements in GRAND CANYON pivotal cohort, initiation of CIRRUS-HCM trial, and expansion of LYNX trial in Duchenne were key highlights. The Company also reported cash, cash equivalents, and marketable securities of approximately $532.8 million as of March 31, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.26%
Tags
Rhea-AI Summary

Edgewise Therapeutics, Inc. (Nasdaq: EWTX) has appointed Arlene Morris, a seasoned biotechnology industry veteran, to its Board of Directors. With over 30 years of experience in executive management and board roles, Morris brings invaluable expertise in strategic development and operational excellence to the company. As the CEO of Willow Advisors, she advises biotech companies on financing, strategy, and business development. Her previous roles include leading public biotechnology companies like Syndax Pharmaceuticals and Affymax. Edgewise Therapeutics looks forward to leveraging Morris' wealth of experience to advance its mission of helping patients and families affected by serious muscle diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
management
-
Rhea-AI Summary

Edgewise Therapeutics, Inc. (Nasdaq: EWTX) has dosed the first patient in the Phase 2 CIRRUS-HCM trial of EDG-7500, a novel oral cardiac sarcomere modulator designed to address issues associated with obstructive Hypertrophic Cardiomyopathy (HCM). The trial will assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with obstructive HCM. Positive preclinical data has led to the advancement of EDG-7500 into this trial, showing encouraging effects on left ventricular outflow tract gradient relief and ventricular function. The company expects to report data from the trial in the third quarter of 2024 and plans to initiate further trials in the second half of 2024 and fourth quarter of 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.2%
Tags
-
Rhea-AI Summary
Edgewise Therapeutics, Inc. receives Orphan Drug Designations from the European Medicines Agency for Sevasemten (EDG-5506) in the treatment of Becker and Duchenne Muscular Dystrophies. Sevasemten aims to prevent muscle damage and is in late-stage clinical trials. The designation provides regulatory benefits and market exclusivity for up to 10 years in the EU.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.78%
Tags
Rhea-AI Summary
Edgewise Therapeutics announces positive two-year topline results from the ARCH Open Label Trial of Sevasemten in adults with Becker Muscular Dystrophy, showing stabilization of NSAA scores, significant decreases in muscle damage biomarkers, and favorable safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags

FAQ

What is the current stock price of Edgewise Therapeutics (EWTX)?

The current stock price of Edgewise Therapeutics (EWTX) is $34 as of November 1, 2024.

What is the market cap of Edgewise Therapeutics (EWTX)?

The market cap of Edgewise Therapeutics (EWTX) is approximately 3.2B.

What is Edgewise Therapeutics, Inc.?

Edgewise Therapeutics, Inc. is a biotechnology company focused on developing novel therapies for severe, rare muscle disorders.

Where is Edgewise Therapeutics located?

Edgewise Therapeutics is headquartered in Boulder, Colorado.

What is the core focus of Edgewise Therapeutics?

The company focuses on the discovery, development, and commercialization of treatments for musculoskeletal diseases.

What are Edgewise Therapeutics' key projects?

Its key projects involve developing orally bioavailable, small molecule therapies for rare muscle disorders.

Who financed Edgewise Therapeutics' Series A round?

The company's Series A financing was provided by OrbiMed.

Is Edgewise Therapeutics a public company?

Yes, Edgewise Therapeutics is a public company listed on NASDAQ under the symbol EWTX.

What recent achievements has Edgewise Therapeutics made?

The company has made significant progress in its clinical trials and expanded its research partnerships.

What kind of diseases is Edgewise Therapeutics targeting?

Edgewise Therapeutics targets severe, rare muscle disorders involving skeletal muscle.

What type of therapies is Edgewise Therapeutics developing?

The company is developing orally bioavailable, small molecule therapies.

What makes Edgewise Therapeutics' treatments innovative?

Their treatments aim to offer improved patient outcomes and enhanced quality of life by leveraging advanced research methodologies and cutting-edge technology.

Edgewise Therapeutics, Inc.

Nasdaq:EWTX

EWTX Rankings

EWTX Stock Data

3.18B
93.77M
0.47%
112.31%
9.05%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOULDER